Apyx Medical Corp: Form 10-Q/A for the period ended Sep 30, 2018
Filed with the SEC on May 8, 2020 and accepted by EDGAR at May 8, 2020, 13:59 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-07-01 to 2018-09-30 | $3.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2018-01-01 to 2018-09-30 | $10.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2018-07-01 to 2018-09-30 | $1.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2018-01-01 to 2018-09-30 | $3.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2018-07-01 to 2018-09-30 | $2.5m | us-gaap:GrossProfit |
| Gross profit | 9 months2018-01-01 to 2018-09-30 | $7.3m | us-gaap:GrossProfit |
| Research and development | 3 months2018-07-01 to 2018-09-30 | $613.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2018-01-01 to 2018-09-30 | $1.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2018-07-01 to 2018-09-30 | $1.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2018-01-01 to 2018-09-30 | $6.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | −$2.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-01-01 to 2018-09-30 | −$8.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2018-07-01 to 2018-09-30 | −$2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2018-01-01 to 2018-09-30 | −$2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-07-01 to 2018-09-30 | $68.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2018-01-01 to 2018-09-30 | $67.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | $1.96 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2018-01-01 to 2018-09-30 | $1.98 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-07-01 to 2018-09-30 | $2.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2018-01-01 to 2018-09-30 | $2.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-07-01 to 2018-09-30 | 34,934,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2018-01-01 to 2018-09-30 | 33,952,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2018-01-01 to 2018-09-30 | −$2.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2018-01-01 to 2018-09-30 | $203.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-09-30 | $40.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $106.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $113.2m | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $22.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $22.6m | us-gaap:Liabilities |
| Long-term debt | At period end2018-09-30 | $0 | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2018-09-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2018-09-30 | $90.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000719135-20-000035. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.